Legal & General Group
LBRX

Legal & General Group’s LB Pharmaceuticals LBRX Stock Holding History

Legal & General Group’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.5K Sell
1,723
-155
-8% -$3.58K ﹤0.01% 2715
2025
Q4 		$41.8K Buy
+1,878
New +$32.8K ﹤0.01% 2773

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Legal & General Group's LBRX Position: Q1 2026 in Review

Legal & General Group reduced its LB Pharmaceuticals (LBRX) stake by 8.3% in Q1 2026, selling an estimated $3.58K and leaving 1,723 shares worth $42.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2715.

Legal & General Group first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Legal & General Group held 1,723 shares of LB Pharmaceuticals worth $42.5K as of Q1 2026.
  • Legal & General Group sold 155 LB Pharmaceuticals shares in Q1 2026, an estimated $3.58K.
  • LB Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2715 holding.
  • Legal & General Group first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.